Lowell, MA – May 23, 2014 – InfoBionic™, an emerging digital health company focused on superior patient monitoring solutions for chronic disease management, announced it was named a 2014 TiE50 Award Finalist for top technology start-ups by TiE Silicon Valley at their annual conference, TiEcon, last week in Santa Clara, CA. TiE recognizes technology start-ups that shine because of their innovative products and sharp business tactics.
InfoBionic was selected as a finalist for the TiE50 Award from a pool of over 2,800 start-ups from 27 countries. Entrants were judged on the merits of the company’s business model, the technology’s intellectual property value and the leadership team.
“It is an honor and a privilege for InfoBionic to be chosen as a finalist for the prominent TiE50 Award,” stated Dr. Ravi Kuppuraj, Chief Technical Officer and co-founder of InfoBionic. “This further validates the value InfoBionic brings to the healthcare monitoring marketplace. We look forward to building on this momentum with the commercialization of our first product, the MoMe System, for arrhythmia monitoring later this year.”
The MoMe System, a cloud-based remote patient monitoring system for arrhythmia monitoring, has received CE Mark approval in Europe and U.S. Food and Drug (FDA) 510(k) clearance is expected later this year.
Dr. Kuppuraj will be speaking at TiEcon East in Cambridge, MA on Friday, May 30th as part of the Connected Health panel.
About the Award
TiE50 is TiE Silicon Valley’s premier annual awards program keenly contested by thousands of technology startups worldwide. Awards are announced at TiEcon, the world’s largest conference for entrepreneurs, each year in May. The TiE50 awards program incorporates standard multiple regression techniques combined with a comprehensive evaluation, screening and judging process.
About the MoMe System
The MoMe™ System is the first cloud-based remote patient monitoring platform that provides real-time patient data, unprecedented analytics with Multi-Pass Analysis, and seamless conversion between Holter, Event, and Mobile Cardiovascular Telemetry (MCT) monitoring modes. The system is poised to revolutionize the $3B worldwide cardiac monitoring market by delivering superior arrhythmia detection and on-demand access to patient data for diagnosis.
About InfoBionic, Inc.
InfoBionic™ is an emerging digital health company that is dedicated to providing anytime, anywhere access to patient monitoring data with improved event detection and clinical efficacy through a lower cost business model. The InfoBionic MoMe™ System offers a superior remote patient monitoring platform for chronic diseases with an initial market focus on cardiac arrhythmias.
For more information please visit www.infobionic.ai.
MEDIA CONTACT:
Katie Arnold
SPRIG Consulting LLC
(408) 805-0520
katie@sprigconsulting.com